Cocrystal Pharma (COCP) appoints antiviral veteran to board
Rhea-AI Filing Summary
Cocrystal Pharma, Inc. appointed Carol L. Brosgart, MD to its Board of Directors, effective August 12, 2026, and announced this in a press release dated August 17, 2026. The company describes itself as a clinical-stage biotechnology company developing antiviral therapeutics targeting noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses.
Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, government service, and biopharmaceutical consulting, including key roles in the development and regulatory approval of antiviral therapies Viread® and Hepsera® at Gilead Sciences. Cocrystal’s leadership highlights her anticipated contributions to the clinical development of CDI-988 for norovirus and to the broader antiviral pipeline.
Positive
- None.
Negative
- None.
Insights
Analyzing...
8-K Event Classification
Key Figures
Key Terms
Regulation FD regulatory
clinical-stage biotechnology company medical
norovirus medical
structure-based technologies technical
antiviral therapeutics medical
FAQ
What board change did Cocrystal Pharma (COCP) announce on August 17, 2026?
Who is Carol L. Brosgart, the new Cocrystal Pharma (COCP) board member?
What relevant drug development experience does Carol Brosgart bring to Cocrystal Pharma (COCP)?
How does Cocrystal Pharma (COCP) describe its business focus in this disclosure?
Which Cocrystal Pharma (COCP) program is specifically mentioned with Carol Brosgart’s appointment?
What is the effective date of Carol Brosgart’s appointment to the Cocrystal Pharma (COCP) board?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
(State or other Jurisdiction of Incorporation) |
(Commission File Number) |
(IRS Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s
telephone number, including area code:
(Former name or former address, if changed since last report.): n/a
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging
growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
| Title of Each Class | Trading Symbol(s) | Name of each exchange on which registered | ||
(The Nasdaq Capital Market) |
Item 7.01 Regulation FD Disclosure
On August 17, 2026, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing the appointment of Carol L. Brosgart, MD to the Company’s Board of Directors. A copy of the press release is furnished as Exhibit 99.1.
The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities under such section, and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933 or the Exchange Act.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit | Description | |
| 99.1 | Press Release dated August 17, 2026 | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Cocrystal Pharma, Inc. | ||
| Date: August 17, 2026 | By: | /s/ James Martin |
| Name: | James Martin | |
| Title: | Chief Financial Officer | |
Exhibit 99.1
Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors
BOTHELL, Wash., August 17, 2026 — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments, today announced the appointment of Carol Brosgart, MD to its Board of Directors, effective August 12, 2026. Dr. Brosgart brings several decades of experience in antiviral therapy, epidemiology, and biopharma advisory.
“Dr. Brosgart holds a distinguished record in antiviral drug development, having contributed to the development and FDA approval of therapies that have benefited patients worldwide,” said Roger Kornberg, Ph.D., Chairman of the Board, Chief Scientist, and Chairman of Scientific Advisory Board at Cocrystal and Nobel laureate. “Her clinical and scientific insights will be invaluable as we work to advance the clinical development of CDI-988 for norovirus, as well as the broader development of our antiviral pipeline.”
James Sapirstein, Chief Executive Officer of Cocrystal Pharma added, “I’ve had the privilege of knowing Carol since she was a key opinion leader during the HIV epidemic, working with her as a colleague at Gilead, and later having her join me at Tobira. Few people bring her combination of clinical rigor and real-world drug development experience, and I couldn’t be more pleased to have her insight guiding Cocrystal at this pivotal stage.”
Dr. Brosgart has extensive experience in government service and biopharmaceutical consulting, has served on the boards of numerous biotechnology companies, and was the founding Medical Director of the East Bay AIDS Center at Alta Bates Medical Center in Berkeley, California. She is a member of the Board of Directors of the Hepatitis B Foundation, previously co-chaired the National Task Force on Hepatitis B and was a Senior Advisor on Science and Policy to the Division of Viral Hepatitis at the CDC and the Viral Hepatitis Action Coalition at the CDC Foundation. She currently sits on the Boards of Directors of Galmed Pharmaceuticals, Eradivir Biotech, and Merlin Biotech, and previously held board positions at Abivax, Mirum Pharmaceuticals, Tobira Therapeutics and Juvaris. Dr. Brosgart spent more than a decade at Gilead Sciences as well, where she played a critical role in the development and regulatory approval of the antiviral therapies Viread® and Hepsera®. She received her M.D. from the University of California, San Francisco (UCSF) School of Medicine, where she currently serves as a Clinical Professor of Medicine, Biostatistics and Epidemiology.
About Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of noroviruses, influenza viruses, coronaviruses (including SARS-CoV-2), and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create viable antiviral drugs. For more information, visit www.cocrystalpharma.com.
Investor Contact:
Nic Johnson
Russo Partners
nic.johnson@russopartnersllc.com
(303) 482-6405
Media Contact:
David Schull
Russo Partners
david.schull@russopartnersllc.com
(858) 717-2310